Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/12/2019
SIETES contiene 92856 citas

 
 
 1 a 20 de 81 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Azzouz B, Morel A, Kanagaratman L, Herlem E, Trenque T. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf 2019;42:diciembre. [Ref.ID 103209]
2. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
4.Enlace a cita original Cita con resumen
Gao Y, O'Caoimh R, Healy L, Kerins DM, Eustace J, Guyatt G, Sammon D, Molloy DW. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013;3:22 de julio. [Ref.ID 95839]
6.Enlace a cita original
Montero Corominas D, García del Pozo J, de Abajo FJ. Utilización de antihipertensivos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-14. [Ref.ID 86455]
7. Cita con resumen
Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Golf Jr DC. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension. Results from the Cardiovascular Health Study. Arch Intern Med 2009;169:1195-202. [Ref.ID 86332]
8.Tiene citas relacionadas Cita con resumen
Kunz R, Wolbers M, Glass T, Mann JFE. The COOPERATE trial: a letter of concern. Lancet 2008;371:1575-6. [Ref.ID 82871]
9. Cita con resumen
Hansen ML, Gislason GH, Kober L, Schramm TK, Folke F, Buch P, Abildstrom SZ, Madsen M, Rasmussen S, Torp-Pedersen C. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008;65:217-23. [Ref.ID 82225]
10.Tiene citas relacionadas Cita con resumen
Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29. [Ref.ID 81943]
11.Tiene citas relacionadas
Potter BJ, Lelorier J. Effect of ramipril on the incidence of diabetes. N Engl J Med 2007;356:522-3. [Ref.ID 79082]
12.Tiene citas relacionadas
Bangalore S, Messerli FH. Effect of ramipril on the incidence of diabetes. N Engl J Med 2007;356:522. [Ref.ID 79081]
13.
LeBlanc JM, Dasta JF, Pruchnicki MC, Schentag JJ. Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors. J Clin Pharmacol 2006;46:968-80. [Ref.ID 78008]
15.Tiene citas relacionadas Cita con resumen
Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006;368:555-6. [Ref.ID 77807]
16. Cita con resumen
Messerli FH, Mancia G, Conti R, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006;144:884-93. [Ref.ID 77365]
17.
Momma K. ACE Inhibitors in pediatric patients with heart failure. Pediatr Drugs 2006;8:55-69. [Ref.ID 76688]
18. Cita con resumen
19.
Ross S, Macleod MJ. Antihypertensive drug prescribing in Grampian. Br J Clin Pharmacol 2005;60:300-5. [Ref.ID 74717]
20. Cita con resumen
McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89. [Ref.ID 73990]
Seleccionar todas
 
 1 a 20 de 81 siguiente >>